Acute pancreatitis following L-asparaginase in acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is the most frequent malignancy in children,representing 25–30% of all childhood malignancies. Although treatment outcome has improved owing to advances in chemotherapy, there is still a group of patients who experience severe adverse events. L-Asparaginase is an e...

Descripción completa

Detalles Bibliográficos
Autores principales: M'harzi, Soulaimane, Elouali, Aziza, Lahrache, Karim, Ghanam, Ayad, Babakhouya, Abdeladim, Rkain, Maria, Benajiba, Noufissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668613/
https://www.ncbi.nlm.nih.gov/pubmed/36405565
http://dx.doi.org/10.1016/j.lrr.2022.100357
Descripción
Sumario:Acute lymphoblastic leukemia (ALL) is the most frequent malignancy in children,representing 25–30% of all childhood malignancies. Although treatment outcome has improved owing to advances in chemotherapy, there is still a group of patients who experience severe adverse events. L-Asparaginase is an effective antineoplastic agent used in chemotherapy of ALL. Despite its indisputable indication, it can cause various adverse effects, including acute pancreatitis (AP). Recently, an increase in the number of pediatric AP cases following L-Asparaginase in Acute Lymphoblastic Leukemia been reported. We presented a case of acute pancreatitis in children with ALL induced by administration of L-ASPA preparations.

Ejemplares similares